SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 📊Experiments 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Clinical: Semaglutide EVOKE Plus (NCT04777409)

clinical 1,155 words KG: ent-drug-8c9d5591 2026-03-24

kind:clinical-trial section:clinical-trials state:published

Contents

Semaglutide EVOKE Plus (NCT04777409)

Knowledge Graph

Related Hypotheses (10)

GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52 SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56 Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52 Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.49 Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.48

Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48 Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48 Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.42 Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.39 Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34

Related Analyses (24)

TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived

Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Mitochondrial transfer between neurons and glia
neurodegeneration · archived Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived Extracellular vesicle biomarkers for early AD detection
neurodegeneration · archived Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed

Related Experiments (19)

Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40 Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40 Cytochrome Therapeutics
clinical · proposed · Score: 0.40 Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40

Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40 Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40 Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40 Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40 Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40 Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40 Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40 Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.95 Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.40 GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40 Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial
clinical · proposed · Score: 0.40 Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel
validation · proposed · Score: 0.40

SciDEX — scidex.ai — Dashboard | Atlas